Here you can find the abstracts of biobank research projects in year 2014, which use the samples from Auria Biobank.

Biobank research projects each year: 

2015  |  2016  |  2017

The expression and predictive value of biomarkers in gastric cancer

Olli Carpén, Institute of Biomedicine, UTU

Gastric cancer is the third most common cause of cancer deaths worldwide. The research, encompassing 300 different gastric cancer samples, analyses the clinical characteristics of molecular sub-types of gastric cancer using immunohistochemical methods. An additional aim of the research is to identify novel prognostic biomarkers and drug targets for gastric cancer. Better biomarkers help to identify the special characteristics of gastric cancer and the most suitable treatment for each patient. New drug targets help in designing future treatment trials.

Study on the epidemiologyical expression and treatment of acromegaly in the Hospital District of Southwest Finland following operative treatment

Novartis Finland Oy

Acromegaly is a rare disorder in which a tumour in the pituitary gland leads to excess production of growth hormone. The study aims to determine the number of acromegaly patients who achieve inadequate biochemical control following the removal of the pituitary gland tumour, and the number of patients who require somatostatin analog therapy to achieve the desired response. The study additionally aims to determine the status of other disorders caused by acromegaly in patients who have not achieved biochemical control compared to patients who have achieved control. The study sheds new light on targeted therapy for acromegaly patients.

Genetic predisposition to breast cancer in high-risk breast cancer families

Minna Kankuri-Tammilehto, Clinical Genetics, TYKS
Johanna Schleutker, Medical Genetics, UTU

One in every nine women will be diagnosed with breast cancer at some point in their life. According to estimates, 5–10% of breast cancer cases are hereditary, i.e. due to being a carrier of a genetic mutation that predisposes the patient to a high risk of cancer, in which case the breast cancer risk during the patient’s lifetime is more than 40%. The study maps the local breast cancer gene mutations in the TYKS expert responsibility area (ERA). Mutations in the BRCA1/2 gene were the cause of only approx. 25% of cases of hereditary breast cancer. The aim of the study is to identify previously unknown genes predisposing high-risk patients to breast cancer. The study furthermore aims to gain new information about the combined effect of various risk genes and about how various predisposing genes are associated with the age of occurrence. The results of the research are used in diagnosing breast cancer, in determining the prognosis and in assessing the cancer risk.

A study of beta cell PET tracers in tissue samples

Pirjo Nuutila, PET Centre, UTU

Diabetes results when beta cells, which produce insulin in the pancreas, are destroyed. Roughly 180 million people worldwide are estimated to have diabetes. Pancreatic studies are complicated by the location of the pancreas deep in the abdomen and the small number of beta cells. By the time the disease is diagnosed, most of the insulin-producing beta cells have already been destroyed. The study aims to develop novel tracers for the PET (positron emission tomography) imaging of insulin-producing beta cells in the pancreas. Such tracers could potentially allow the progression of diabetes to be monitored more closely and improve the possibilities of tracking the effectiveness of diabetes medications.

The expression of somatostatin receptors in gliomas and correlation to prognostic markers

Heikki Minn and Aida Kiviniemi, Oncology Clinic, TYKS

Gliomas are the most common type of brain tumour and are classified according to their histological degree of malignancy into either low-grade or high-grade gliomas, i.e. malignant gliomas. In recent years, several molecular-pathological tracers have been introduced, allowing gliomas to be divided more accurately into sub-types for treatment and monitoring. Many tumours express somatostatin receptors, which are used as a target for therapy, especially in the treatment of neuroendocrine tumours. There are indications that the expression of somatostatin receptors in gliomas can serve as both a diagnostic and prognostic marker. The study aims to determine the expression of somatostatin receptors in gliomas and its correlation to the patient’s survival predictors and molecular markers. According to the research hypothesis, the expression of somatostatin receptors in gliomas is a potential new prognostic biomarker that clarifies diagnostic classification and aids in selecting a suitable treatment.

Study on the epidemiologyical expression of myelofibrosis, polycythemia vera and essential thrombocythemia and the overall survival of myelofibrosis patients at the time of diagnosis in the Southwest Finland Hospital District

Study on the epidemiologyical expression of myelofibrosis, polycythemia vera and essential thrombocythemia and the overall survival of myelofibrosis patients at the time of diagnosis in the Southwest Finland Hospital District

Novartis Finland Oy

Myelofibrosis is a slowly progressing disease with a poor prognosis. Only in recent years has progress been made in improving patients’ overall survival through medical treatment. In some patients, myelofibrosis transforms into leukaemia, and the study aims to determine the number of myelofibrosis patients who develop acute leukaemia and the significance of the JAK2V617F gene mutation in its development. The research brings new information to light about the epidemiology of myelofibrosis and factors affecting its prognosis.